Efficacy and safety of fixed dose combination of arterolane maleate and piperaquine phosphate dispersible tablets in paediatric patients with acute uncomplicated Plasmodium falciparum malaria: a phase II, multicentric, open-label study

Table 1 Demographic and baseline clinical characteristics

	FDC of arterolane maleate + piperaquine phosphate (n = 141)
Sex, n (%)
Male	73 (52 %)
Female	68 (48 %)
Age (6 months to ≤12 years), n	141
Median	5.11
Mean ± SD (min, max)	5.9 ± 3.45 (0.06, 12.11)
Age group 1 (6 months to <2 years), n	22
Median	1.05
Mean ± SD (min, max)	0.9 ± 0.39 (0.06, 1.11)
Age group 2 (2 to <6 years), n	49
Median	4.00
Mean ± SD (min, max)	3.8 ± 1.07 (2.00, 5.11)
Age group 3 (6 to ≤12 years), n	70
Median	9.00
Mean ± SD (min, max)	8.8 ± 1.83 (6.00,12.11)
Race, n (%)
African	123 (87 %)
Asian	18 (13 %)
Height (cm)
Median	106.00
Mean ± SD (min, max)	105.7 ± 19.24 (58.00,146.00)
Weight (kg)
Median	17.00
Mean ± SD (min, max)	18.5 ± 6.84 (7.00, 36.00)
Baseline axillary temperature (°C)
Median	38.20
Mean ± SD (min, max)	38.4 ± 0.88 (36.50, 40.50)
No. of baseline P. falciparum asexual parasites (µL⁻¹)
Median	44,720.00
Mean ± SD (min, max)	45,428.6 ± 31,481.95 (1040.00, 99,860.00)

ISSN: 1475-2875